Results 81 to 90 of about 41,957 (164)

Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease.

JAMA Dermatol, 2023
Baumrin E, Baker LX, Byrne M, Martin PJ, Flowers ME, Onstad L, El Jurdi N, Chen H, Beeghly-Fadiel A, Lee SJ, Tkaczyk ER.   +10 more
europepmc   +1 more source

Erosive Tarsal Conjunctival Lesions Following Immunogenic Events in Early Development of Ocular Graft-vs-Host Disease. [PDF]

Life (Basel)
Kohnstam MG, Surico PL, Luo ZK.
europepmc   +1 more source

Histopathologic Grading of Acute Cutaneous Graft-vs-Host Disease and Nonrelapse Mortality.

JAMA Dermatol
Chen J, Raymundo C, Martinez A, Lee SJ, Stevenson PA, Shinohara MM.   +5 more
europepmc   +1 more source

Study protocol: Close Assessment and Testing for Chronic Graft-vs.-Host disease (CATCH). [PDF]

PLoS One
Pidala J, Carpenter PA, Onstad L, Pavletic SZ, Hamilton BK, Chen GL, Farhadfar N, Hall M, Lee SJ.   +8 more
europepmc   +1 more source

Outcomes of Importance to Patients Living With Cutaneous Chronic Graft-vs-Host Disease.

JAMA Dermatol
Baumrin E, Cronholm PF, Kearney MD, Mengesha M, Cesar LG, Keddem S, Schapira MM, Lee SJ, Loren AW, Gelfand JM.   +9 more
europepmc   +1 more source

Cost-Effectiveness of Extracorporeal Photopheresis in Patients With Chronic Graft-vs-Host Disease. [PDF]

J Health Econ Outcomes Res
Peacock A, Dehle FC, Mesa Zapata OA, Gennari F, Williams MRI, Hamad N, Larsen S, Harrison SJ, Taylor C.   +8 more
europepmc   +1 more source

Editorial: Cellular Therapies: Past, Present and Future

Frontiers in Immunology, 2018
Ralf Dressel, Hildegard T. Greinix, Ernst Holler, Anne M. Dickinson   +3 more
doaj   +1 more source

Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial. [PDF]

Int J Hematol
Teshima T, Onishi Y, Kato K, Taniguchi S, Miyamura K, Fukushima K, Kato J, Ishikawa T, Doki N, Nakamae H, Maeda Y, Inamoto Y, Okada M, Maki A, Shimada F, Tajima T, Wroclawska M, Zeiser R, Onizuka M.   +18 more
europepmc   +1 more source

The Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft vs. Host Disease on Treatment Patterns and Outcomes-A Single-Center Longitudinal Cohort Analysis. [PDF]

Cancers (Basel)
Fridberg G, Amit O, Karni C, Tshernichovsky D, Shasha D, Rouach V, Varssano D, Bar-Shai A, Goldberg I, Wasserman G, Avivi I, Ram R.   +11 more
europepmc   +1 more source